Research Progress on PD-1/PD-L1 Inhibitors in Treatment of Advanced, Relapsed, and Refractory NK/T-cell Lymphoma
10.3971/j.issn.1000-8578.2025.25.0060
- VernacularTitle:PD-1/PD-L1抑制剂治疗晚期复发难治NK/T细胞淋巴瘤研究进展
- Author:
Jing YANG
1
;
Tao WU
1
Author Information
1. Department of Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China;Department of Oncology, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang 550004, China;Department of Oncology, School of Clinical Medicine, Guizhou Medical University, Guiyang 550004, China.
- Publication Type:REVIEWS
- Keywords:
Extranodal NK/T cell lymphoma;
Relapsed and refractory;
Immunotherapy;
Immune checkpoint inhibitor;
PD-1;
PD-L1
- From:
Cancer Research on Prevention and Treatment
2025;52(8):705-710
- CountryChina
- Language:Chinese
-
Abstract:
Extranodal NK/T cell lymphoma (ENKTL) is a rare subtype of extranodal non-Hodgkin lymphoma (NHL) with strong invasiveness. Although the chemotherapy regimen based on asparaginase is the standard treatment for advanced patients, the prognosis needs to be improved. Moreover, treatment options are limited for recurrent or refractory patients who have failed chemotherapy. In recent years, the research progress of the programmed cell death receptor-1 (PD-1)/programmed cell death ligand-1 (PD-L1) immune checkpoint inhibitor has provided a new perspective for ENKTL treatment. This article summarizes the role of PD-1/PD-L1 in the pathogenesis of ENKTL and the regulatory factors of PD-L1 expression. It also explores the differences in the PD-1/PD-L1 expression in ENKTL of different molecular typing systems as well as the application prospects of their inhibitors in the treatment of ENKTL.
